{"id":"W3103606205","doi":"10.1136/jitc-2020-sitc2020.0307","title":"307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Pritzker School of Medicine; American Society of Hematology","keywords":"Vemurafenib; Internal medicine; Medicine; Atezolizumab; Hazard ratio; Oncology; Progression-free survival; Melanoma; Pembrolizumab; Immunotherapy; Cancer research; Cancer; Overall survival; Metastatic melanoma; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001374704,0.0005611978,0.001259735,0.0001547834,0.0002621761,0.0007117881,0.0003610272,0.0005106766,0.002176299],"category_scores_gemma":[0.0006001029,0.0002846688,0.001520901,0.0002126638,0.00030919,0.0003413529,0.0002524566,0.001092993,0.0004689617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004396966,"about_ca_system_score_gemma":0.000724222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005968795,"about_ca_topic_score_gemma":0.001994019,"domain_scores_codex":[0.9996508,0.0001721763,0.00002278203,0.00005716903,0.00003084629,0.00006613893],"domain_scores_gemma":[0.9995758,0.00007084593,0.0001010329,0.00005251143,0.00002916022,0.0001705779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8315962,0.01029985,0.06184182,0.0004421223,0.00303867,0.0002495746,0.00009447566,0.001548764,0.02726946,0.0002242318,0.007797039,0.05559776],"study_design_scores_gemma":[0.4599849,0.1976891,0.3176811,0.0001361483,0.005201667,0.0007746153,0.0001516472,0.005009988,0.006068602,0.0008308642,0.006334043,0.0001373065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968809,0.0009569397,0.0001308451,0.0002201332,0.00006855277,0.0001908152,0.0007319091,0.00001858638,0.0008013661],"genre_scores_gemma":[0.9966027,0.0003614527,0.0002843326,0.0004452523,0.0001201342,0.0002189029,0.001475787,0.000007107031,0.000484353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002176299,"threshold_uncertainty_score":0.007280409,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00991258563327047,"score_gpt":0.2194322897048243,"score_spread":0.2095197040715538,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}